Journal Article (Review Article)

DKFZ-2025-02662

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases.

Tigu, A.-B. ; Nistor, M. ; Gulei, D. ; Constantinescu, C.-S. ; Kegyes, D. ; Cenariu, D. ; Muresan, X. ; Munteanu, R. ; Feder, R. ; Jitaru, C. ; Bancos, A. ; Santa, M. ; Tomai, R. ; Damian, M. ; Ivancuta, A. ; Rus, I. ; Bojan, A. ; Zdrenghea, M. ; Buzoianu, A.-D. ; Tanase, A. ; Einsele, H. ; Kobold, S.DKFZ* ; Tomuleasa, C.

2025
Harcourt Burlington, Mass.

Abstract: Chimeric Antigen Receptor (CAR) T cell therapy, initially developed for hematologic malignancies, has recently emerged as a promising modality for treating autoimmune diseases. This review explores the evolving role of CAR T cells in reprogramming immune tolerance and achieving durable remission in autoimmune disorders. By engineering T cells to target pathogenic B cells or autoreactive T cells, CAR T therapy offers a targeted and potentially curative approach for diseases such as systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes. Early clinical trials and preclinical models have demonstrated the feasibility, safety, and efficacy of CD19-targeted CAR T cells in depleting autoreactive B cells and restoring immune homeostasis. Furthermore, next-generation CAR designs-including regulatory T cell-based CARs and antigen-specific constructs-highlight the growing precision and versatility of this platform. Despite these advances, challenges remain, including potential toxicity, antigen escape, and the need for long-term immune monitoring. This review summarizes current findings, delineates mechanistic insights, and discusses future directions for optimizing CAR T cell therapies in the context of autoimmunity.

Keyword(s): Autoimmune diseases ; CAR T cells ; Emerging therapies

Note: epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle München (MU01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---